Search | Clinical Trials Finder

Conditions: Metabolic Syndrome
Interventions: Simvastatin, Vytorin, Placebo, Ezetimibe; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 47
States / cities: Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: any statin, niacin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
Interventions: Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet, Placebo Oral Tablet, Placebo oral capsule; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Lincoln, California • Miami, Florida • Louisville, Kentucky + 1 more

Conditions: Hypercholesterolaemia
Interventions: Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more

Conditions: Hyperlipidemia
Interventions: Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 18
States / cities: Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more

Conditions: Chronic Acalculous Cholecystitis
Interventions: ezetimibe, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypercholesterolemia
Interventions: ezetimibe, Placebo; Drug
Lead sponsor: Radiant Research; Other
Eligibility: 21 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Sacramento, California • Golden, Colorado • Miami, Florida + 13 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Ezetimibe, Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 65
States / cities: Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Rosuvastatin, Ezetimibe, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 54
States / cities: Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more

Conditions: Peripheral Arterial Disease
Interventions: Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA); Drug · Behavioral · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hyperlipidemias
Interventions: Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos; Combination Product · Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more

Conditions: Dyslipidemia
Interventions: AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Hyperlipidemia
Interventions: Evolocumab, Placebo to Evolocumab, Ezetimibe, Placebo to Ezetimibe; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 20
States / cities: Carmichael, California • Los Angeles, California • Mission Viejo, California + 15 more

Conditions: Type 1 Diabetes Mellitus, Dyslipidemia
Interventions: Simvastatin, Ezetimibe/Simvastatin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Hypercholesterolemia
Interventions: Enlicitide, Ezetimibe, Bempedoic Acid, Placebo for Enlicitide, Placebo for Ezetimibe, Placebo for Bempedoic Acid; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Lincoln, California • Flossmoor, Illinois • Louisville, Kentucky + 4 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Hyperlipidemia
Interventions: AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more

Conditions: Hyperlipidemia
Interventions: Evacetrapib, Atorvastatin, Ezetimibe, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 61
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more

Search by objective public record fields.

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

The Influence of Ezetimibe on Gallbladder Function

Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol